PAVM - PAVmed Inc.
Pre-market:
| Previous close | 0.4599 |
| Open | 0.4700 |
| Bid | 0.4480 x 1100 |
| Ask | 0.4850 x 3200 |
| Day's range | 0.4500 - 0.4724 |
| 52-week range | 0.3500 - 2.3400 |
| Volume | |
| Avg. volume | 486,350 |
| Market cap | 48.096M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
PAVmed and Lucid Diagnostics Provide Strategic Business Update
NEW YORK, January 17, 2023--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. ("Veris"), a private digital health company focused on enhanced personalized cancer care, today provided a
- Business Wire
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
NEW YORK, January 11, 2023--Companies will present refinements to their business strategy as each continue to the benefit patients in need and create value for shareholders.
- Business Wire
PAVmed Partners with Novosound on Ultrasound Imaging Technology
NEW YORK, December 22, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd. ("Novosound"), a venture-backed technology company based in Glasgow, Scotland, to explore applying Novosound’s proprietary flexible thin-film ultrasound technology in me
- Business Wire
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
NEW YORK, December 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), has commercially launched its Veris Cancer Care Platform™ ("Veris CCP"). Veris executed its first commercial contract with New Jersey Cancer Care, PA ("NJCC"), a leading oncology practice and membe
- Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
NEW YORK, December 08, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that the Company was selected as one of ten finalists for the Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry ("MD+DI"), a leading publication serving manufacturers of medical devices and in vitro diagnostics products,
- Business Wire
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
NEW YORK, December 01, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device ("EsoCheck") at the American Association for Cancer Research’s ("AACR") Special Conference: Precision Prevention, Early Detect
- Business Wire
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.
- Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.
- Business Wire
PAVmed to Participate in BTIG Digital Health Forum
NEW YORK, November 11, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed", the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and CEO, will participate in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST at the BTIG Digital Health Foru
- Business Wire
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK, November 10, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Lishan Aklog, M.D., the Lucid’s Chairman and Chief Executive Officer, will present an overview of the Company at the CG MedTech, Diagnostics and Digital Health & Services Forum taking place on November 17, 2022 from 11:00 am to 11:25 am EST
- Business Wire
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
NEW YORK, November 09, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices ("EsoCheck") at Coastline International, Inc. ("Coastline"), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico. The Company has work
- Business Wire
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
NEW YORK, November 03, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call and webcast on Tuesday, November 15, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s operations and its growth strategy. In addition, Dennis McGrath, PAVmed’s President and Chief Financi
- Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
NEW YORK, November 02, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman, and Chief Executive Officer, will provide a business update including an overview of the Company’s operation
- Business Wire
PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference
NEW YORK, August 30, 2022--PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference
- Business Wire
PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK, August 16, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and six months ended June 30, 2022.
- Business Wire
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK, August 15, 2022--Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
- Business Wire
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
NEW YORK, August 11, 2022--Lucid Diagnostics Inc. announced its subsidiary, LucidDx Labs Inc., launched four new Lucid Test Centers in California, Texas Florida and Ohio.
- Business Wire
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
NEW YORK, August 04, 2022--Newly published AGA update supports esophageal precancer screening to prevent esophageal cancer using EsoGuard on samples collected with its EsoCheck.
- Business Wire
PAVmed to Hold a Business Update Conference Call on August 16, 2022
NEW YORK, August 03, 2022--PAVmed Inc. announced that the Company will host a business update conference call on Tuesday, August 16, 2022, at 4:30 PM EDT.
- Business Wire
PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America
NEW YORK, July 19, 2022--PAVmed's Chairman & CEO Lishan Aklog, M.D. was selected as one of the Most Influential Black Executives in Corporate America in 2022 by Savoy Magazine
- Business Wire
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
NEW YORK, July 18, 2022--Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
